Anti-Insulin Receptor (phospho Y1158) antibody (ab78355)

Overview

  • Product nameAnti-Insulin Receptor (phospho Y1158) antibody
    See all Insulin Receptor primary antibodies
  • Description
    Rabbit polyclonal to Insulin Receptor (phospho Y1158)
  • Specificityab78355 recognizes Insulin Receptor when phosphorylated at Tyr1158, and Insulin like Growth Factor 1 Receptor (IGF1R) Tyr1131.
  • Tested applicationsSuitable for: ICC, WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic peptide corresponding to the amino acid region encompassing the human, mouse, and rat phospho Insulin Receptor Tyrosine 1158 and Insulin like Growth Factor 1 Receptor (IGF1R) Tyrosine 1131.

  • Positive control
    • Insulin treated lysates from CHO cells transfected with Insulin Receptor; pervanadate treated Jurkat cell lysate; pervanadate treated lysates from L6 cells.

Properties

Applications

Our Abpromise guarantee covers the use of ab78355 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC
WB
  • Application notesICC: Use at an assay dependent dilution.
    WB: 1/1000. Predicted molecular weight: 156 kDa.
    IHC: Use at an assay dependent dilution.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionReceptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.
    • Tissue specificityIsoform Long and isoform Short are predominantly expressed in tissue targets of insulin metabolic effects: liver, adipose tissue and skeletal muscle but are also expressed in the peripheral nerve, kidney, pulmonary alveoli, pancreatic acini, placenta vascular endothelium, fibroblasts, monocytes, granulocytes, erythrocytes and skin. Isoform Short is preferentially expressed in fetal cells such as fetal fibroblasts, muscle, liver and kidney. Found as a hybrid receptor with IGF1R in muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at protein level). Overexpressed in several tumors, including breast, colon, lung, ovary, and thyroid carcinomas.
    • Involvement in diseaseRabson-Mendenhall syndrome
      Leprechaunism
      Diabetes mellitus, non-insulin-dependent
      Familial hyperinsulinemic hypoglycemia 5
      Insulin-resistant diabetes mellitus with acanthosis nigricans type A
    • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily.
      Contains 3 fibronectin type-III domains.
      Contains 1 protein kinase domain.
    • DomainThe tetrameric insulin receptor binds insulin via non-identical regions from two alpha chains, primarily via the C-terminal region of the first INSR alpha chain. Residues from the leucine-rich N-terminus of the other INSR alpha chain also contribute to this insulin binding site. A secondary insulin-binding site is formed by residues at the junction of fibronectin type-III domain 1 and 2.
    • Post-translational
      modifications
      After being transported from the endoplasmic reticulum to the Golgi apparatus, the single glycosylated precursor is further glycosylated and then cleaved, followed by its transport to the plasma membrane.
      Autophosphorylated on tyrosine residues in response to insulin. Phosphorylation of Tyr-999 is required for binding to IRS1, SHC1 and STAT5B. Dephosphorylated by PTPRE at Tyr-999, Tyr-1185, Tyr-1189 and Tyr-1190. Dephosphorylated by PTPRF and PTPN1. Dephosphorylated by PTPN2; down-regulates insulin-induced signaling.
    • Cellular localizationCell membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • CD220 antibody
      • HHF5 antibody
      • human insulin receptor antibody
      • Insr antibody
      • INSR_HUMAN antibody
      • Insulin receptor subunit beta antibody
      • IR 1 antibody
      • IR antibody
      • IR-1 antibody
      • IR1 antibody
      see all

    Anti-Insulin Receptor (phospho Y1158) antibody images

    • All lanes : Anti-Insulin Receptor (phospho Y1158) antibody (ab78355) at 1/1000 dilution

      Lane 1 : CHO cell lysates transfected with Insulin Receptor, untreated
      Lane 2 : CHO cell lysates transfected with Insulin Receptor, insulin treated
      Lane 3 : CHO cell lysates transfected with Insulin Receptor, insulin treated with immunizing peptide

      Developed using the ECL technique

      Predicted band size : 156 kDa
      Observed band size : 125 kDa (why is the actual band size different from the predicted?)
    • Anti-Insulin Receptor (phospho Y1158) antibody (ab78355) at 1/1000 dilution + pervanadate treated Jurkat cell lysate

      Secondary
      goat anti-rabbit HRP conjugated IgG at 1/5000 dilution
      Developed using the ECL technique

      Predicted band size : 156 kDa
      Observed band size : 156 kDa
      Additional bands at : 36 kDa,75 kDa. We are unsure as to the identity of these extra bands.
    • All lanes : Anti-Insulin Receptor (phospho Y1158) antibody (ab78355) at 1/1000 dilution

      Lane 1 : L6 cell lysates, untreated
      Lane 2 : L6 cell lysates, pervanadate treated

      Secondary
      goat anti-rabbit HRP conjugated IgG at 1/5000 dilution
      Developed using the ECL technique

      Predicted band size : 156 kDa
      Observed band size : 156 kDa
      Additional bands at : 100 kDa,85 kDa. We are unsure as to the identity of these extra bands.

    References for Anti-Insulin Receptor (phospho Y1158) antibody (ab78355)

    ab78355 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab78355.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"